Back to Cardiology
Cardiologyv2020Evidence-Based

CHADS-65 (Canadian Society of Cardiology Guideline)

Clinical decision algorithm developed by the Canadian Cardiovascular Society to guide antithrombotic therapy for patients with nonvalvular atrial fibrillation or atrial flutter. Uses age-based approach to determine whether patients should receive oral anticoagulation, antiplatelet therapy, or no antithrombotic therapy for stroke prevention.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
chads 65 recommendation
—algorithm
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The CHADS-65 (Canadian Society of Cardiology Guideline) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within cardiology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Decision Algorithm: Step 1: Age ≥65? → OAC. Step 2: CHADS₂ risk factors present? → OAC. Step 3: Vascular disease present? → ASA. Otherwise → No therapy.

Clinical Pearls & Practice Notes

  • CHADS-65 is a decision algorithm, not a numerical scoring system
  • Primary decision point: Age ≥65 years automatically qualifies for anticoagulation
  • CHADS₂ risk factors: CHF, Hypertension, Age ≥75, Diabetes, Stroke/TIA history
  • For CHADS-65, age cutoff is 65 years (not 75 as in traditional CHADS₂)
  • Direct oral anticoagulants (DOACs) preferred over warfarin
  • ASA dose recommendation: 81mg daily for vascular disease patients
  • Combination ASA + OAC beyond 1 year not recommended (bleeding risk)
  • Algorithm designed for nonvalvular atrial fibrillation and atrial flutter
  • Annual stroke risk: 2.1% for ages 65-74, 4.4% for ages ≥75
  • Endorsed with Strong Recommendation, High-Quality Evidence (CCS 2020)
  • Simplifies decision-making compared to complex numerical risk scores
  • Age alone (≥65) is sufficient indication for anticoagulation
  • For recent coronary stents, consult interventional cardiologist for combination therapy
  • Annual reassessment recommended as patient risk factors may change
  • Algorithm emphasizes practical clinical decision-making
  • Designed for emergency departments and primary care settings

Evidence & Literature Citations

  1. Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2020 Dec;36(12):1847-1948. doi: 10.1016/j.cjca.2020.09.001.
  2. Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2014 Oct;30(10):1114-30. doi: 10.1016/j.cjca.2014.08.001.
  3. Canadian Agency for Drugs and Technologies in Health (CADTH). CHAD65 and CHA2DS2-VASc Risk Stratification Tools for Patients with Atrial Fibrillation: A Review of Clinical Effectiveness and Guidelines. Ottawa: CADTH; 2019 Mar.
  4. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584.

Score Interpretation Ranges

Oral Anticoagulation1 – 1 pts

Age ≥65 or CHADS₂ risk factors present

Antiplatelet Therapy2 – 2 pts

Age <65, no CHADS₂ risk factors, vascular disease present

No Antithrombotic Therapy3 – 3 pts

Age <65, no CHADS₂ risk factors, no vascular disease

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.